Shares of Biogen Inc (NASDAQ:BIIB) have been given an average rating of “Buy” by the thirty-three brokerages that are presently covering the firm, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $348.99.
Several brokerages have recently weighed in on BIIB. BidaskClub upgraded Biogen from a “hold” rating to a “buy” rating in a research note on Friday. SunTrust Banks assumed coverage on shares of Biogen in a research report on Wednesday, September 20th. They set a “buy” rating and a $360.00 price target on the stock. Mizuho reaffirmed a “neutral” rating and set a $319.00 price target (up previously from $274.00) on shares of Biogen in a research report on Wednesday, September 13th. Raymond James Financial cut shares of Biogen from a “strong-buy” rating to a “market perform” rating and increased their price target for the stock from $244.28 to $319.00 in a research report on Thursday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $340.00 price target on shares of Biogen in a research report on Wednesday, October 25th.
Shares of Biogen (NASDAQ:BIIB) traded up $0.44 during trading on Friday, hitting $340.43. The stock had a trading volume of 512,388 shares, compared to its average volume of 1,070,000. The company has a quick ratio of 1.90, a current ratio of 2.19 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $71,990.00, a P/E ratio of 20.87, a PEG ratio of 1.95 and a beta of 0.73. Biogen has a 12 month low of $244.28 and a 12 month high of $348.84.
In other Biogen news, CEO Michel Vounatsos bought 780 shares of the business’s stock in a transaction on Saturday, December 29th. The shares were purchased at an average price of $320.55 per share, with a total value of $250,029.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,879 shares of the company’s stock, valued at approximately $1,563,963.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alexander J. Denner bought 30,000 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was acquired at an average cost of $317.36 per share, for a total transaction of $9,520,800.00. Following the acquisition, the director now directly owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The disclosure for this purchase can be found here. Insiders acquired 31,560 shares of company stock worth $10,020,858 in the last three months. 0.25% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Biogen by 2.3% during the second quarter. BlackRock Inc. now owns 18,107,358 shares of the biotechnology company’s stock valued at $4,913,612,000 after buying an additional 415,099 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Biogen by 1.3% during the second quarter. Vanguard Group Inc. now owns 14,534,827 shares of the biotechnology company’s stock valued at $3,944,171,000 after buying an additional 182,337 shares during the last quarter. State Street Corp raised its holdings in shares of Biogen by 1.5% during the second quarter. State Street Corp now owns 9,721,312 shares of the biotechnology company’s stock valued at $2,637,973,000 after buying an additional 140,929 shares during the last quarter. FMR LLC raised its holdings in shares of Biogen by 10.1% during the second quarter. FMR LLC now owns 6,104,026 shares of the biotechnology company’s stock valued at $1,656,390,000 after buying an additional 561,436 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Biogen by 8.0% during the second quarter. Northern Trust Corp now owns 3,017,136 shares of the biotechnology company’s stock valued at $818,731,000 after buying an additional 223,371 shares during the last quarter. 88.11% of the stock is currently owned by institutional investors.
WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/biogen-inc-biib-given-average-recommendation-of-buy-by-analysts.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.